Exosomes: an innovative therapeutic target for cerebral ischemia-reperfusion injury

Ischemic stroke is caused by artery stenosis or occlusion, which reduces blood flow and may cause brain damage. Treatment includes restoring blood supply; however, ischemia-reperfusion can still aggravate tissue injury. Reperfusion injury can increase levels of reactive oxygen species, exacerbate mi...

詳細記述

書誌詳細
出版年:Frontiers in Pharmacology
主要な著者: Yuan Yang, Yushan Duan, Jinxi Yue, Yue Yin, Yiming Ma, Xiaohong Wan, Jianlin Shao
フォーマット: 論文
言語:英語
出版事項: Frontiers Media S.A. 2025-03-01
主題:
オンライン・アクセス:https://www.frontiersin.org/articles/10.3389/fphar.2025.1552500/full
その他の書誌記述
要約:Ischemic stroke is caused by artery stenosis or occlusion, which reduces blood flow and may cause brain damage. Treatment includes restoring blood supply; however, ischemia-reperfusion can still aggravate tissue injury. Reperfusion injury can increase levels of reactive oxygen species, exacerbate mitochondrial dysfunction, create excessive autophagy and ferroptosis, and cause inflammation during microglial infiltration. Cerebral ischemia-reperfusion injury (CIRI) is a key challenge in the treatment of ischemic stroke. Currently, thrombolysis (e.g., rt-PA therapy) and mechanical thrombectomy are the primary treatments, but their application is restricted by narrow therapeutic windows (<4.5 h) and risks of hemorrhagic complications. Exosomes reduce CIRI by regulating oxidative stress, mitochondrial autophagy, inflammatory responses, and glial cell polarization. In addition, their noncellular characteristics provide a safer alternative to stem cell therapy. This article reviews the research progress of exosomes in CIRI in recent years.
ISSN:1663-9812